Share Price and Basic Stock Data
Last Updated: February 11, 2026, 8:49 pm
| PEG Ratio | -0.76 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Hemant Surgical Industries Ltd operates within the Medical Equipment & Accessories sector, reporting a current market capitalization of ₹383 Cr and a share price of ₹293. The company has demonstrated a steady revenue trajectory, with sales recorded at ₹109 Cr for the fiscal year ending March 2023, an increase from ₹101 Cr in the previous year. However, sales have shown fluctuations in the most recent quarters, with ₹58 Cr realized in March 2024, followed by a slight decline to ₹48 Cr in September 2023. The trailing twelve months (TTM) sales stand at ₹122 Cr, indicating a positive growth trend compared to prior years. This growth reflects the company’s ability to adapt to market demands and maintain a competitive edge, though the recent quarterly figures suggest potential challenges in sustaining momentum. The operating profit margin (OPM) has fluctuated, peaking at 13% in March 2024, which may indicate operational efficiency improvements, but declined to 7% in September 2023, warranting further analysis of cost management strategies.
Profitability and Efficiency Metrics
Hemant Surgical Industries Ltd reported a net profit of ₹8 Cr for the fiscal year ending March 2023, up from ₹5 Cr in March 2022, reflecting a robust net profit margin of 7.54% for the same period. The company’s profitability metrics, including a return on equity (ROE) of 13.6% and a return on capital employed (ROCE) of 16.4%, are indicative of effective utilization of shareholder funds and capital. The interest coverage ratio (ICR) stands at a healthy 6.40x, suggesting that the company can comfortably meet its interest obligations. However, the cash conversion cycle (CCC) has lengthened to 87 days as of March 2025, indicating potential inefficiencies in inventory and receivables management compared to the sector average. Operating profit recorded a decline to ₹9 Cr for FY 2025 from ₹10 Cr in FY 2024, suggesting challenges in maintaining operational efficiency. The company’s ability to sustain profitability amidst fluctuating sales and rising operational costs will be a critical factor moving forward.
Balance Sheet Strength and Financial Ratios
The balance sheet of Hemant Surgical Industries Ltd reflects a solid foundation, with total assets standing at ₹214 Cr as of September 2025, up from ₹148 Cr in March 2025. The company holds reserves of ₹110 Cr, indicating a strong equity position. Borrowings have increased to ₹53 Cr, suggesting an uptick in leverage but still maintaining a manageable debt-to-equity ratio of 0.49. The current ratio is reported at 1.45, indicating good short-term liquidity, while the quick ratio of 0.74 suggests some reliance on inventory for liquidity, which may pose risks if sales falter. The price-to-book value (P/BV) ratio is recorded at 1.65x, suggesting that the market values the company’s equity slightly above its book value, a sentiment that can be interpreted positively in terms of market confidence. However, the increase in borrowings and the longer cash conversion cycle may raise concerns about financial flexibility and operational efficiency.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Hemant Surgical Industries Ltd reveals a significant concentration of ownership among promoters, who hold 58.90% of the shares as of September 2025, down from 73.56% in previous periods. This shift could indicate a move towards more diversified ownership, with institutional investors holding 10.81% and foreign institutional investors (FIIs) at a mere 0.15%. The public’s stake has increased to 30.13%, reflecting growing investor interest. The number of shareholders has also fluctuated, with 758 recorded as of September 2025, indicating a potential increase in retail investor participation. The growing presence of domestic institutional investors (DIIs) at 10.81% may enhance stability and confidence in the company’s prospects. However, the decline in promoter shareholding could raise questions about long-term commitment and control over the company’s strategic direction.
Outlook, Risks, and Final Insight
Looking ahead, Hemant Surgical Industries Ltd faces both opportunities and challenges. The company’s ability to capitalize on its recent sales growth and improve operational efficiencies will be critical in sustaining profitability. However, risks such as fluctuating sales figures, a prolonged cash conversion cycle, and increasing leverage could impact financial stability. Additionally, the changing shareholding pattern may influence investor sentiment and market perception. The company must navigate these challenges while leveraging its strong balance sheet and profitability metrics to enhance operational capabilities. If the company can effectively manage its costs and optimize its inventory and receivables processes, it may position itself favorably in the competitive medical equipment landscape. Conversely, failure to address these operational inefficiencies could hinder growth prospects and investor confidence.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Hemant Surgical Industries Ltd | 383 Cr. | 293 | 367/88.2 | 36.9 | 94.3 | 0.00 % | 16.4 % | 13.6 % | 10.0 |
| Industry Average | 383.00 Cr | 293.00 | 36.90 | 94.30 | 0.00% | 16.40% | 13.60% | 10.00 |
Quarterly Result
| Metric | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|
| Sales | 51 | 58 | 48 | 58 | 49 | 58 | 64 |
| Expenses | 47 | 52 | 44 | 51 | 45 | 52 | 57 |
| Operating Profit | 4 | 6 | 3 | 7 | 4 | 6 | 8 |
| OPM % | 8% | 11% | 7% | 13% | 7% | 10% | 12% |
| Other Income | 1 | 1 | 3 | 2 | 2 | 3 | 2 |
| Interest | 1 | 1 | 1 | 0 | 1 | 1 | 2 |
| Depreciation | 0 | 0 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 4 | 6 | 5 | 8 | 4 | 6 | 7 |
| Tax % | 36% | 18% | 17% | 27% | 29% | 18% | 25% |
| Net Profit | 2 | 5 | 4 | 6 | 3 | 5 | 5 |
| EPS in Rs | 48.12 | 6.93 | 3.75 | 5.63 | 3.05 | 4.74 | 4.15 |
Last Updated: January 1, 2026, 10:16 am
Below is a detailed analysis of the quarterly data for Hemant Surgical Industries Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 64.00 Cr.. The value appears strong and on an upward trend. It has increased from 58.00 Cr. (Mar 2025) to 64.00 Cr., marking an increase of 6.00 Cr..
- For Expenses, as of Sep 2025, the value is 57.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 52.00 Cr. (Mar 2025) to 57.00 Cr., marking an increase of 5.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 8.00 Cr.. The value appears strong and on an upward trend. It has increased from 6.00 Cr. (Mar 2025) to 8.00 Cr., marking an increase of 2.00 Cr..
- For OPM %, as of Sep 2025, the value is 12.00%. The value appears strong and on an upward trend. It has increased from 10.00% (Mar 2025) to 12.00%, marking an increase of 2.00%.
- For Other Income, as of Sep 2025, the value is 2.00 Cr.. The value appears to be declining and may need further review. It has decreased from 3.00 Cr. (Mar 2025) to 2.00 Cr., marking a decrease of 1.00 Cr..
- For Interest, as of Sep 2025, the value is 2.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.00 Cr. (Mar 2025) to 2.00 Cr., marking an increase of 1.00 Cr..
- For Depreciation, as of Sep 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 7.00 Cr.. The value appears strong and on an upward trend. It has increased from 6.00 Cr. (Mar 2025) to 7.00 Cr., marking an increase of 1.00 Cr..
- For Tax %, as of Sep 2025, the value is 25.00%. The value appears to be increasing, which may not be favorable. It has increased from 18.00% (Mar 2025) to 25.00%, marking an increase of 7.00%.
- For Net Profit, as of Sep 2025, the value is 5.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 5.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 4.15. The value appears to be declining and may need further review. It has decreased from 4.74 (Mar 2025) to 4.15, marking a decrease of 0.59.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:14 am
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 51 | 56 | 56 | 60 | 101 | 109 | 106 | 107 | 122 |
| Expenses | 48 | 53 | 53 | 57 | 95 | 98 | 95 | 97 | 109 |
| Operating Profit | 2 | 3 | 3 | 3 | 6 | 11 | 10 | 9 | 13 |
| OPM % | 5% | 5% | 5% | 5% | 6% | 10% | 10% | 9% | 11% |
| Other Income | 0 | 0 | 0 | 1 | 2 | 2 | 4 | 5 | 5 |
| Interest | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 2 | 3 |
| Depreciation | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 1 | 1 | 1 | 1 | 6 | 10 | 13 | 11 | 13 |
| Tax % | 10% | 8% | 41% | 9% | 25% | 24% | 23% | 23% | |
| Net Profit | 1 | 1 | 0 | 1 | 5 | 8 | 10 | 8 | 10 |
| EPS in Rs | 50.76 | 61.02 | 27.00 | 73.43 | 248.92 | 9.95 | 9.39 | 7.79 | 8.89 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2018-2019 | 2019-2020 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | -100.00% | 400.00% | 60.00% | 25.00% | -20.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | -100.00% | 500.00% | -340.00% | -35.00% | -45.00% |
Hemant Surgical Industries Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 6 years from 2018-2019 to 2024-2025.
Growth
Last Updated: September 5, 2025, 6:30 am
Balance Sheet
Last Updated: December 10, 2025, 2:49 am
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 2 | 2 | 2 | 8 | 10 | 10 | 13 |
| Reserves | 5 | 6 | 5 | 8 | 11 | 16 | 44 | 53 | 110 |
| Borrowings | 9 | 11 | 14 | 14 | 10 | 7 | 7 | 31 | 53 |
| Other Liabilities | 12 | 14 | 23 | 15 | 32 | 34 | 38 | 54 | 39 |
| Total Liabilities | 28 | 33 | 44 | 40 | 54 | 65 | 100 | 148 | 214 |
| Fixed Assets | 7 | 8 | 10 | 11 | 12 | 13 | 18 | 40 | 34 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 17 |
| Investments | 0 | 0 | 1 | 0 | 1 | 0 | 5 | 1 | 3 |
| Other Assets | 21 | 25 | 33 | 29 | 42 | 51 | 77 | 94 | 160 |
| Total Assets | 28 | 33 | 44 | 40 | 54 | 65 | 100 | 148 | 214 |
Below is a detailed analysis of the balance sheet data for Hemant Surgical Industries Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 13.00 Cr.. The value appears strong and on an upward trend. It has increased from 10.00 Cr. (Mar 2025) to 13.00 Cr., marking an increase of 3.00 Cr..
- For Reserves, as of Sep 2025, the value is 110.00 Cr.. The value appears strong and on an upward trend. It has increased from 53.00 Cr. (Mar 2025) to 110.00 Cr., marking an increase of 57.00 Cr..
- For Borrowings, as of Sep 2025, the value is 53.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 31.00 Cr. (Mar 2025) to 53.00 Cr., marking an increase of 22.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 39.00 Cr.. The value appears to be improving (decreasing). It has decreased from 54.00 Cr. (Mar 2025) to 39.00 Cr., marking a decrease of 15.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 214.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 148.00 Cr. (Mar 2025) to 214.00 Cr., marking an increase of 66.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 34.00 Cr.. The value appears to be declining and may need further review. It has decreased from 40.00 Cr. (Mar 2025) to 34.00 Cr., marking a decrease of 6.00 Cr..
- For CWIP, as of Sep 2025, the value is 17.00 Cr.. The value appears strong and on an upward trend. It has increased from 12.00 Cr. (Mar 2025) to 17.00 Cr., marking an increase of 5.00 Cr..
- For Investments, as of Sep 2025, the value is 3.00 Cr.. The value appears strong and on an upward trend. It has increased from 1.00 Cr. (Mar 2025) to 3.00 Cr., marking an increase of 2.00 Cr..
- For Other Assets, as of Sep 2025, the value is 160.00 Cr.. The value appears strong and on an upward trend. It has increased from 94.00 Cr. (Mar 2025) to 160.00 Cr., marking an increase of 66.00 Cr..
- For Total Assets, as of Sep 2025, the value is 214.00 Cr.. The value appears strong and on an upward trend. It has increased from 148.00 Cr. (Mar 2025) to 214.00 Cr., marking an increase of 66.00 Cr..
Notably, the Reserves (110.00 Cr.) exceed the Borrowings (53.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -7.00 | -8.00 | -11.00 | -11.00 | -4.00 | 4.00 | 3.00 | -22.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 35 | 36 | 35 | 26 | 56 | 58 | 75 | 70 |
| Inventory Days | 64 | 73 | 125 | 113 | 57 | 67 | 99 | 205 |
| Days Payable | 102 | 97 | 143 | 89 | 92 | 110 | 116 | 188 |
| Cash Conversion Cycle | -3 | 12 | 17 | 51 | 21 | 15 | 58 | 87 |
| Working Capital Days | 12 | 23 | -28 | 41 | -19 | 2 | 52 | 61 |
| ROCE % | 15% | 12% | 14% | 32% | 45% | 30% | 16% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 |
|---|---|
| FaceValue | 10.00 |
| Basic EPS (Rs.) | 7.70 |
| Diluted EPS (Rs.) | 7.70 |
| Cash EPS (Rs.) | 9.07 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 60.51 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 60.51 |
| Revenue From Operations / Share (Rs.) | 102.14 |
| PBDIT / Share (Rs.) | 13.50 |
| PBIT / Share (Rs.) | 12.14 |
| PBT / Share (Rs.) | 10.02 |
| Net Profit / Share (Rs.) | 7.70 |
| NP After MI And SOA / Share (Rs.) | 7.70 |
| PBDIT Margin (%) | 13.21 |
| PBIT Margin (%) | 11.88 |
| PBT Margin (%) | 9.81 |
| Net Profit Margin (%) | 7.54 |
| NP After MI And SOA Margin (%) | 7.54 |
| Return on Networth / Equity (%) | 12.72 |
| Return on Capital Employeed (%) | 14.55 |
| Return On Assets (%) | 5.42 |
| Long Term Debt / Equity (X) | 0.36 |
| Total Debt / Equity (X) | 0.49 |
| Current Ratio (X) | 1.45 |
| Quick Ratio (X) | 0.74 |
| Interest Coverage Ratio (X) | 6.40 |
| Interest Coverage Ratio (Post Tax) (X) | 4.65 |
| Enterprise Value (Cr.) | 125.52 |
| EV / Net Operating Revenue (X) | 1.18 |
| EV / EBITDA (X) | 8.90 |
| MarketCap / Net Operating Revenue (X) | 0.97 |
| Price / BV (X) | 1.65 |
| Price / Net Operating Revenue (X) | 0.97 |
| EarningsYield | 0.07 |
After reviewing the key financial ratios for Hemant Surgical Industries Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. No previous period data is available for comparison.
- For Basic EPS (Rs.), as of Mar 25, the value is 7.70. This value is within the healthy range. No previous period data is available for comparison.
- For Diluted EPS (Rs.), as of Mar 25, the value is 7.70. This value is within the healthy range. No previous period data is available for comparison.
- For Cash EPS (Rs.), as of Mar 25, the value is 9.07. This value is within the healthy range. No previous period data is available for comparison.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 60.51. No previous period data is available for comparison.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 60.51. No previous period data is available for comparison.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 102.14. No previous period data is available for comparison.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 13.50. This value is within the healthy range. No previous period data is available for comparison.
- For PBIT / Share (Rs.), as of Mar 25, the value is 12.14. This value is within the healthy range. No previous period data is available for comparison.
- For PBT / Share (Rs.), as of Mar 25, the value is 10.02. This value is within the healthy range. No previous period data is available for comparison.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 7.70. This value is within the healthy range. No previous period data is available for comparison.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 7.70. This value is within the healthy range. No previous period data is available for comparison.
- For PBDIT Margin (%), as of Mar 25, the value is 13.21. This value is within the healthy range. No previous period data is available for comparison.
- For PBIT Margin (%), as of Mar 25, the value is 11.88. This value is within the healthy range. No previous period data is available for comparison.
- For PBT Margin (%), as of Mar 25, the value is 9.81. This value is below the healthy minimum of 10. No previous period data is available for comparison.
- For Net Profit Margin (%), as of Mar 25, the value is 7.54. This value is within the healthy range. No previous period data is available for comparison.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 7.54. This value is below the healthy minimum of 8. No previous period data is available for comparison.
- For Return on Networth / Equity (%), as of Mar 25, the value is 12.72. This value is below the healthy minimum of 15. No previous period data is available for comparison.
- For Return on Capital Employeed (%), as of Mar 25, the value is 14.55. This value is within the healthy range. No previous period data is available for comparison.
- For Return On Assets (%), as of Mar 25, the value is 5.42. This value is within the healthy range. No previous period data is available for comparison.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.36. This value is within the healthy range. No previous period data is available for comparison.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.49. This value is within the healthy range. No previous period data is available for comparison.
- For Current Ratio (X), as of Mar 25, the value is 1.45. This value is below the healthy minimum of 1.5. No previous period data is available for comparison.
- For Quick Ratio (X), as of Mar 25, the value is 0.74. This value is below the healthy minimum of 1. No previous period data is available for comparison.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 6.40. This value is within the healthy range. No previous period data is available for comparison.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 4.65. This value is within the healthy range. No previous period data is available for comparison.
- For Enterprise Value (Cr.), as of Mar 25, the value is 125.52. No previous period data is available for comparison.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.18. This value is within the healthy range. No previous period data is available for comparison.
- For EV / EBITDA (X), as of Mar 25, the value is 8.90. This value is within the healthy range. No previous period data is available for comparison.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.97. This value is below the healthy minimum of 1. No previous period data is available for comparison.
- For Price / BV (X), as of Mar 25, the value is 1.65. This value is within the healthy range. No previous period data is available for comparison.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.97. This value is below the healthy minimum of 1. No previous period data is available for comparison.
- For EarningsYield, as of Mar 25, the value is 0.07. This value is below the healthy minimum of 5. No previous period data is available for comparison.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Hemant Surgical Industries Ltd:
- Net Profit Margin: 7.54%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 14.55% (Industry Average ROCE: 16.4%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 12.72% (Industry Average ROE: 13.6%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 4.65
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.74
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 36.9 (Industry average Stock P/E: 36.9)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.49
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 7.54%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Medical Equipment & Accessories | 502, 5th Floor, Ecstasy Business Park Co-Op Socteiy Limited, Mumbai Maharashtra 400080 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Hanskumar Shah | Chairman & Managing Director |
| Mr. Kaushik Hanskumar Shah | WholeTime Director & CFO |
| Mr. Hemant Praful Shah | Whole Time Director |
| Mrs. Nehal Babu Karelia | Non Executive Director |
| Mr. Ketan Chandrakat Dave | Independent Director |
| Mrs. Kshama Dharnidharka | Independent Director |
FAQ
What is the intrinsic value of Hemant Surgical Industries Ltd?
Hemant Surgical Industries Ltd's intrinsic value (as of 12 February 2026) is ₹198.31 which is 32.32% lower the current market price of ₹293.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹383 Cr. market cap, FY2025-2026 high/low of ₹367/88.2, reserves of ₹110 Cr, and liabilities of ₹214 Cr.
What is the Market Cap of Hemant Surgical Industries Ltd?
The Market Cap of Hemant Surgical Industries Ltd is 383 Cr..
What is the current Stock Price of Hemant Surgical Industries Ltd as on 12 February 2026?
The current stock price of Hemant Surgical Industries Ltd as on 12 February 2026 is ₹293.
What is the High / Low of Hemant Surgical Industries Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Hemant Surgical Industries Ltd stocks is ₹367/88.2.
What is the Stock P/E of Hemant Surgical Industries Ltd?
The Stock P/E of Hemant Surgical Industries Ltd is 36.9.
What is the Book Value of Hemant Surgical Industries Ltd?
The Book Value of Hemant Surgical Industries Ltd is 94.3.
What is the Dividend Yield of Hemant Surgical Industries Ltd?
The Dividend Yield of Hemant Surgical Industries Ltd is 0.00 %.
What is the ROCE of Hemant Surgical Industries Ltd?
The ROCE of Hemant Surgical Industries Ltd is 16.4 %.
What is the ROE of Hemant Surgical Industries Ltd?
The ROE of Hemant Surgical Industries Ltd is 13.6 %.
What is the Face Value of Hemant Surgical Industries Ltd?
The Face Value of Hemant Surgical Industries Ltd is 10.0.